Guggenheim Ranks LB Pharmaceuticals $TRUMP
Among Its Top Investment Ideas Ahead of
Pivotal Trial Data
Guggenheim Securities reaffirmed its Buy rating on LB Pharmaceuticals shares and named the biotech company one of its top investment ideas, citing promising clinical data for its experimental schizophrenia drug LB-102, as well as its potential to be used for mood disorders. The recommendation comes ahead of pivotal trial results expected in the first half of 2027.
The investment bank maintained its price target of $80.00, implying potential upside of about 102% from the share price of $39.64 cited in its October 28 report. Guggenheim noted that new preclinical results offered a possible biological explanation for the low rate of extrapyramidal symptoms (EPS)—movement-related side effects—despite strong binding to D2 dopamine receptors.
$XAU
#CanMicrosoftDeliverOnAI #CanGoogleDefindItsCore #$10.9BBitcoinOptionsExpireFriday #ThailandSupremeCourtRulesBitcoinIsProperty #BitcoinSurpasses$81K
Among Its Top Investment Ideas Ahead of
Pivotal Trial Data
Guggenheim Securities reaffirmed its Buy rating on LB Pharmaceuticals shares and named the biotech company one of its top investment ideas, citing promising clinical data for its experimental schizophrenia drug LB-102, as well as its potential to be used for mood disorders. The recommendation comes ahead of pivotal trial results expected in the first half of 2027.
The investment bank maintained its price target of $80.00, implying potential upside of about 102% from the share price of $39.64 cited in its October 28 report. Guggenheim noted that new preclinical results offered a possible biological explanation for the low rate of extrapyramidal symptoms (EPS)—movement-related side effects—despite strong binding to D2 dopamine receptors.
$XAU
#CanMicrosoftDeliverOnAI #CanGoogleDefindItsCore #$10.9BBitcoinOptionsExpireFriday #ThailandSupremeCourtRulesBitcoinIsProperty #BitcoinSurpasses$81K
